Current and historical daily PE Ratio for NovoCure Ltd (
) from 2015 to Jul 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. NovoCure stock (NVCR) PE ratio as of Jul 27 2024 is 0.
More Details
NovoCure Ltd (NVCR) PE Ratio (TTM) Chart
NovoCure Ltd (NVCR) PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1214
- 1
- 2
- 3
- 4
- 5
- 6
- 14
NovoCure PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-07-27 | At Loss | 2024-05-21 | At Loss |
2024-07-25 | At Loss | 2024-05-20 | At Loss |
2024-07-24 | At Loss | 2024-05-17 | At Loss |
2024-07-23 | At Loss | 2024-05-16 | At Loss |
2024-07-22 | At Loss | 2024-05-15 | At Loss |
2024-07-19 | At Loss | 2024-05-14 | At Loss |
2024-07-18 | At Loss | 2024-05-13 | At Loss |
2024-07-17 | At Loss | 2024-05-10 | At Loss |
2024-07-16 | At Loss | 2024-05-09 | At Loss |
2024-07-15 | At Loss | 2024-05-08 | At Loss |
2024-07-12 | At Loss | 2024-05-07 | At Loss |
2024-07-11 | At Loss | 2024-05-06 | At Loss |
2024-07-10 | At Loss | 2024-05-03 | At Loss |
2024-07-09 | At Loss | 2024-05-02 | At Loss |
2024-07-08 | At Loss | 2024-05-01 | At Loss |
2024-07-05 | At Loss | 2024-04-30 | At Loss |
2024-07-03 | At Loss | 2024-04-29 | At Loss |
2024-07-02 | At Loss | 2024-04-26 | At Loss |
2024-07-01 | At Loss | 2024-04-25 | At Loss |
2024-06-28 | At Loss | 2024-04-24 | At Loss |
2024-06-27 | At Loss | 2024-04-23 | At Loss |
2024-06-26 | At Loss | 2024-04-22 | At Loss |
2024-06-25 | At Loss | 2024-04-19 | At Loss |
2024-06-24 | At Loss | 2024-04-18 | At Loss |
2024-06-21 | At Loss | 2024-04-17 | At Loss |
2024-06-20 | At Loss | 2024-04-16 | At Loss |
2024-06-18 | At Loss | 2024-04-15 | At Loss |
2024-06-17 | At Loss | 2024-04-12 | At Loss |
2024-06-14 | At Loss | 2024-04-11 | At Loss |
2024-06-13 | At Loss | 2024-04-10 | At Loss |
2024-06-12 | At Loss | 2024-04-09 | At Loss |
2024-06-11 | At Loss | 2024-04-08 | At Loss |
2024-06-10 | At Loss | 2024-04-05 | At Loss |
2024-06-07 | At Loss | 2024-04-04 | At Loss |
2024-06-06 | At Loss | 2024-04-03 | At Loss |
2024-06-05 | At Loss | 2024-04-02 | At Loss |
2024-06-04 | At Loss | 2024-04-01 | At Loss |
2024-06-03 | At Loss | 2024-03-28 | At Loss |
2024-05-31 | At Loss | 2024-03-27 | At Loss |
2024-05-30 | At Loss | 2024-03-26 | At Loss |
2024-05-29 | At Loss | 2024-03-25 | At Loss |
2024-05-28 | At Loss | 2024-03-22 | At Loss |
2024-05-24 | At Loss | 2024-03-21 | At Loss |
2024-05-23 | At Loss | 2024-03-20 | At Loss |
2024-05-22 | At Loss | 2024-03-19 | At Loss |
NovoCure Ltd (NVCR) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![NovoCure Ltd NovoCure Ltd logo](https://static.gurufocus.com/logos/0C0000AZK1.png?14)
NovoCure Ltd
NAICS : 339112
SIC : 5047
ISIN : JE00BYSS4X48
Description
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.